One Foot In The Door? Trio Look To Reenter Annulled EU Generic Tecfidera Market
Positive CHMP Recommendations Follow Biogen Winning February 2025 Exclusivity
A topsy-turvy legal battle going back some years led to a raft of Tecfidera generics being pulled from the market in December last year. Now, three of the affected companies are a step closer to reentering the market, which is set to remain a Tecfidera monopoly until February 2025.
